- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
ULURU Inc. (Amex: ULU) today reported financial results for the second quarter ended June 30,
For the quarter ended June 30, 2008, the net loss attributable to common stockholders was $2,334,000, or $0.04 per share, compared to a net loss of $1,209,000, or $0.02 per share, for the corresponding period in 2007. The second quarter 2008 net loss was impacted by non-cash expenses of $560,000, which included share-based compensation, amortization, and depreciation of $261,000, $269,000 and $30,000, respectively, whereas the second quarter 2007 net loss included non-cash expenses of $405,000, which included share-based compensation, amortization, and depreciation of $119,000, $269,000 and $17,000, respectively.
Revenues for the second quarter of 2008 were $96,000, compared with $119,000 for the same period last year. The decrease of $23,000 in revenues is primarily attributable to a decrease in sponsored research of $35,000, as the prior year revenue was non-recurring.
Total costs and expenses, including amortization and depreciation, increased by $975,000 in the second quarter of 2008 to $2,508,000, as compared with the corresponding period in 2007 where total costs and expenses, including amortization and depreciation, were $1,533,000. The overall expense increase is primarily attributable to increases in Research and Development of $314,000 and increases in Selling, General and Administrative of $648,000. The increase in Research and Development expenses is attributed to additional costs in direct research for Altrazeal(TM) related products of $35,000 and OraDisc(TM) related products of $16,000, increases for our clinical testing programs of $53,000, regulatory consulting and expenses of $66,000, and additional scientific personnel costs, including share-based compensation, of approximately $145,000. The Selling, General and Administrative expense increase was comprised of administrative personnel costs of $299,000, which is inclusive of $134,000 of share-based compensation, along with increased expenses of $323,000 associated with the ramp-up of our initial sales and marketing efforts for our wound care product line.
Interest and miscellaneous income decreased in the second quarter of 2008 to $79,000 as compared with $206,000 for the same period in the previous year. The decrease of $127,000 is attributable to a decrease in interest income due to lower cash balances and lower interest yields in 2008 versus prior year.
Cash and cash equivalents totaled $11,684,000 at June 30, 2008, a decrease of $2,296,000 as compared to our cash and cash equivalents at December 31, 2007 of $13,980,000. The decrease in net cash for the six months ended June 30, 2008 was due primarily to the net cash used in operations of $1,781,000 and the expenditure of $420,000 for manufacturing equipment purchases associated with our OraDisc(TM) and Altrazeal(TM) products.
Commenting on the financial results Kerry P. Gray, President and CEO stated, "With the exception of a delayed receipt of a milestone payment associated with a regulatory filing, our operating results were in line with our forecast projections. The increase in operating expenses are primarily associated with the commercialization and development of our Altrazeal(TM) range of products. To support the launch of Altrazeal(TM), we will continue to invest in our sales and marketing efforts. These efforts are expected to establish key opinion leader support and to develop our business in burn and wound care centers."
During the second quarter we achieved numerous important milestones to include;
-- Launch of Altrazeal(TM);
-- Establishment of our commercial infrastructure, which now includes nine
-- Signing of definitive agreement to acquire Bio Med Sciences, Inc.; and
-- Signing of an additional OraDisc(TM) development agreement.
In conjunction with strategic partners, advancements for of the development of wound care actives in Altrazeal(TM) continues. Additionally, we have advanced the development of Altrazeal(TM) containing silver and anticipate filing a 510k regulatory application with the FDA within the next 60 days.
Gray continued, "We are very pleased with the reception Altrazeal(TM) has received both in burn units and wound care centers. The clinical experience to date is very positive, with the advantages of the Nanoflex technology being demonstrated in a wide variety of difficult to treat wounds. The pre-clinical results including, ease of application, use without a second dressing, accelerated healing, and reduced dressing changes have been demonstrated in numerous wound types. Importantly, patient feedback on the comfort of the dressing and pain has been very positive."
About ULURU Inc.
ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing our innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to future financial performance of ULURU Inc. (the "Company"), the expected launch of our wound dressing product, development of a silver containing product, impact on cost of the production scale-up, the launch of additional products, and our expectation that our licensing fees will increase and offset increased expenses. When used in this press release, the words "may," "targets," "goal," "could," "should," "would," "believe," "feel," "expects," "confident," "anticipate," "estimate," "intend," "plan," "potential" and similar expressions may be indicative of forward-looking statements including without limitation statements relating to the progress of our technology, pre-clinical results for our products and advantages of our products and the consummation of the proposed acquisition of Bio Med Sciences, Inc. These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company’s control. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of an unanticipated event. Further, management cannot assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company’s Annual Report on Form 10-KSB for the year ended December 31, 2007 and other reports filed by us with the Securities and Exchange Commission.
ULURU Inc. SUMMARY OF RESULTS STATEMENTS OF OPERATIONS DATA (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2008 2007 2008 2007 REVENUES License fees $25,522 $16,831 $39,293 $154,880 Royalty income 84,772 81,456 160,346 136,918 Product sales 405 --- 166,878 --- Other (15,000) 20,501 (15,000) 210,501 Total Revenues 95,699 118,788 351,517 502,299 COSTS AND EXPENSES Cost of goods sold 119 --- 137,734 --- Research and development 867,544 553,755 1,742,760 1,119,163 Selling, general and administrative 1,341,235 693,588 2,234,470 1,288,826 Amortization 269,183 268,630 538,367 534,173 Depreciation 30,202 17,173 50,474 33,877 Total Costs and Expenses 2,508,283 1,533,146 4,703,805 2,976,039 OPERATING (LOSS) (2,412,584) (1,414,358) (4,352,288) (2,473,740) Other Income (Expense) Interest and miscellaneous income 78,888 205,825 203,933 419,630 Interest expense --- --- --- (1,574) (LOSS) BEFORE INCOME TAXES (2,333,696) (1,208,533) (4,148,355) (2,055,684) Income taxes --- --- --- --- NET (LOSS) $(2,333,696) $(1,208,533) $(4,148,355) $(2,055,684) Basic and diluted net (loss) per common share $(0.04) $(0.02) $(0.07) $(0.03) WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING 62,466,881 61,916,935 62,445,519 61,326,745 ULURU Inc. SELECTED CONDENSED CONSOLIDATED BALANCE SHEET DATA June 30, 2008 December 31, 2007 (Unaudited) (Audited) Cash and cash equivalents $11,684,039 $13,979,828 Current assets 12,536,715 15,536,146 Property and equipment, net 1,891,882 1,532,881 Other assets 10,664,330 11,053,976 Total assets 25,092,927 28,123,003 Current liabilities 1,432,315 1,389,989 Long term liabilities - deferred revenue 1,055,777 495,281 Total liabilities 2,488,092 1,885,270 Total stockholders’ equity 22,604,835 26,237,733
For more information, please click here
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Graphene under pressure August 26th, 2016
50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016
Graphene under pressure August 26th, 2016
Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016
Nanobiotix revenue for Q2 2016 July 14th, 2016